Marengo Therapeutics

"We believe STAR0602 could be game-changing for patients who fail to respond to checkpoint inhibitors, because it promotes antitumor activity via a very different mechanism, characterized by expansion of a new subset of memory Vβ T cells that reinvigorate the T cell response to tumors." ICYMI: As a follow up to the paper published in Science Translational Medicine, Marengo's CSO Andrew Bayliffe spoke with the team at ACIR.

Attending DIA (Drug Information Association)'s Global Annual Meeting in San Diego? Join Marengo's Chief Development Officer Ke Liu , MD, PhD for their panel session to interpret FDA guidance, discuss trends, and share their own experiences for study design in cell and gene therapy trials.

Wonderful discussion on expediting the #platform to #pipeline journey with Leslie J Williams HC Bioscience, Inc., Rachel W. Humphrey, MD Normunity, Geoffrey McDonough Generation Bio, Mittul Mehta TEVOGEN BIO, Zhen Su, MD MBA Marengo Therapeutics at #longwoodhealthcareleaders Longwood Fund

What an honor to host Brad Loncar (BiotechTV) on site at Marengo Therapeutics and chat about our recent $1.2B partnership with Ipsen focused on our next generation Precision T-cell engager approach to bring more targeted IO therapeutics to "COLD" tumor. Let's to it together as One Team!

🌟 Nasdaq celebrates the extension of the strategic partnership between Marengo Therapeutics and Ipsen! This collaboration continues to drive innovation and growth in the biotech sector for better treatment for patients, setting new standards for success. 🚀 A special thanks to the Nasdaq team for this honor! ATP (Apple Tree Partners) #Nasdaq #Marengo #Ipsen #Biotech #Partnership #oncology

Exciting News! Today Marengo Therapeutics jointly announced our expanded partnership with Ipsen to advance precision T cell engagers from our Tri-STAR platform, targeting difficult-to-treat ‘cold’ tumors. Marengo is eligible to receive up to $1.2 billion plus tiered royalties to progress our mission: The right activation of the right immune cells to promote lifelong protection against cancer Learn more: https://lnkd.in/e4h9-kqu #Biotech #immunooncology #Partnership #Innovation #CancerResearch #Oncology #MarengoTherapeutics #Ipsen

Exciting News! Today Marengo Therapeutics jointly announced our expanded partnership with Ipsen to advance precision T cell engagers from our Tri-STAR platform, targeting difficult-to-treat ‘cold’ tumors. Marengo is eligible to receive up to $1.2 billion plus tiered royalties to progress our mission: The right activation of the right immune cells to promote lifelong protection against cancer Learn more: https://lnkd.in/e4h9-kqu #Biotech #immunooncology #Partnership #Innovation #CancerResearch #Oncology #MarengoTherapeutics #Ipsen

Join Marengo's CEO Zhen Su, MD MBA, who will be speaking at the upcoming Longwood Healthcare Leaders Spring MIT event, June 17 - 18, 2024. More information: https://lnkd.in/exxKDits #longwoodhealthcareleaders #ceo #biotech

Two new team members joined Marengo in May: Please join us in welcoming Mark Jakubowicz and Keana Ramos Baptista. We are thrilled to have you with us! Want to join us? Check out our open roles: https://lnkd.in/eQCzHw7z

The Marengo team were out in Lincoln this week, helping The Food Project for our Spring volunteering event. Each year, The Food Project grows 200,000lbs of food, and donates more than 180,000 servings of produce each year, providing hundreds of thousands of healthy meals to those in need. Marengo spent the morning preparing and clearing plots for new crops and weeding around seedlings... and having fun, despite fending off a lot of spiders in the process! Well done to everyone for taking part. Thank you to The Food Project for hosting us. To learn more about this organization: https://lnkd.in/eTqHb4g